Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAge Labs (BIOA) Common Equity (2023 - 2026)

BioAge Labs' Common Equity history spans 3 years, with the latest figure at $272.1 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 15.81% to $272.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $272.1 million, a 15.81% decrease, with the full-year FY2025 number at $272.1 million, down 15.81% from a year prior.
  • Common Equity hit $272.1 million in Q4 2025 for BioAge Labs, down from $277.5 million in the prior quarter.
  • Over the last five years, Common Equity for BIOA hit a ceiling of $323.1 million in Q4 2024 and a floor of -$197.1 million in Q2 2024.
  • Historically, Common Equity has averaged $137.6 million across 3 years, with a median of $277.5 million in 2025.
  • Biggest five-year swings in Common Equity: skyrocketed 286.35% in 2024 and later fell 15.81% in 2025.
  • Tracing BIOA's Common Equity over 3 years: stood at -$173.4 million in 2023, then skyrocketed by 286.35% to $323.1 million in 2024, then fell by 15.81% to $272.1 million in 2025.
  • Business Quant data shows Common Equity for BIOA at $272.1 million in Q4 2025, $277.5 million in Q3 2025, and $294.8 million in Q2 2025.